Einzeltreffer — DigiBib

The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular in the treatment of cancer.

Titel:	Transfer request (37 CFR 1.821(e)) humanised antibodies to the epidermal growth factor receptor
Autor/in / Beteiligte Person:	Ellis, John Robert Maxwell ; Durrant, Linda Gillian
Link:	View record in USPTO Patent Applications (Volltext)
Veröffentlichung:	2008
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20080260735 Publication Date: October 23, 2008 Appl. No: 12/155986 Application Filed: June 12, 2008 Assignees: ATGen Co. Ltd. (Seongnam-si, KR) Claim: 1. A humanized form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Claim: 2. An antibody as claimed in claim 1, comprising CDRH3 of antibody 340 provided in a human antibody framework. Claim: 3. An antibody as claimed in claim 2, further comprising one or more of the CDRL1, CDRL2, CDRL3, CDRH1, and CDRH2 of antibody 340. Claim: 4. An antibody as claimed in claim 3, comprising the hypervariable region of antibody 340. Claim: 5. An antibody as claimed in claim 1, comprising a substantial portion of the variable region of antibody 340. Claim: 6. An antibody as claimed in claim 5, comprising the variable region as shown in FIG. 2. Claim: 7. An antibody as claimed in claim 1, comprising one of VHb, c, d or e, and one of VKb, c, or d. Claim: 8. An antibody as claimed in claim 7, comprising VHd and VKd or VHd and VKb. Claim: 9. An antibody as claimed in claim 2, wherein the human antibody framework is all or a part of the constant region of a human antibody. Claim: 10. An antibody as claimed in claim 1 linked to a coupling partner or effector molecule. Claim: 11. Nucleic acid encoding an antibody as claimed in claim 1. Claim: 12. A vector having one or more control sequences operably linked to a nucleic acid as claimed in claim 11 to control its expression. Claim: 13. A cell containing nucleic acid as claimed in claim 11. Claim: 14. A method of making an antibody, the method including expression from nucleic acid as claimed in claim 11. Claim: 15. A method as claimed in claim 14, comprising growing a host cell containing nucleic acid encoding a humanized form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428 in culture under appropriate conditions which cause or allow expression of the antibody. Claim: 16. A pharmaceutical composition comprising an antibody as claimed in claim 1 and a pharmaceutically acceptable carrier. Claim: 17. The use of an antibody as claimed in claim 1 in medicine. Claim: 18. The use of an antibody as claimed in claim 1 in the manufacture of a medicament for the treatment or prophylaxis of cancer. Claim: 19. A method for the treatment or prophylaxis of cancer, comprising administering to a subject a therapeutically effective amount of an antibody as claimed in claim 1. Current U.S. Class: 4241/331 Current International Class: 07; 12; 12; 12; 61; 61

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Transfer request (37 CFR 1.821(e)) humanised antibodies to the epidermal growth factor receptor